LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it has filed for approval with the European Medicines Agency for three types of medicine aimed at patients with a chronic obstructive pulmonary disease.

Shares at 1425 GMT down 6.50 pence, or 0.5%, at 1,461.50 pence valuing the company at GBP71.27 billion.

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

December 02, 2016 09:41 ET (14:41 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.